Drug Trial Radar · NCT05650567
Study of M5049 in DM and PM Participants (NEPTUNIA)
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
20
Actual
Start
Jan 19, 2023
Primary completion
Jun 25, 2025
Study completion Jun 25, 2025
Sponsor
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck KGaA, Darmstadt, Germany
- First posted
- Dec 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of orally administered M5049 in idiopathic inflammatory myopathies, specifically dermatomyositis (DM) and polymyositis (PM) participants for 24 weeks.
Conditions
- Dermatomyositis
- Polymyositis
Interventions
M5049 doseDrug
Participants will receive film-coated tablets of M5049 dose orally, twice daily up to 24 weeks.
PlaceboDrug
Participants will receive placebo matched to M5049 orally, twice daily up to 24 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Double Blind Placebo Control Period (DBPC): American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Total Improvement Score (TIS) at Week 24Time frame: At Week 24 (end of DBPC period)
- DBPC Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs)Time frame: Up to Week 26 (Safety follow up)
- DBPC Period: Number of Participants With Clinically Meaningful Changes From Baseline in Laboratory ParametersTime frame: Up to Week 26 (Safety follow up)
- DBPC Period: Number of Participants With Clinically Meaningful Changes From Baseline in Vital SignsTime frame: Up to Week 26 (Safety follow up)
- DBPC Period: Number of Participants With Clinically Meaningful Changes From Baseline in Electrocardiograms (ECG) ParametersTime frame: Up to Week 26 (Safety follow up)
Locations
31 sites in 7 countries. Site status is shown where the registry gives one.
Neuromuscular Research Center
Phoenix, Arizona
HonorHealth Research Institute - Bob Bove Neuroscience Institute-Neuroscience Research
Scottsdale, Arizona
Mayo Clinic Scottsdale (6365)
Scottsdale, Arizona
Barbara Davis Center
Aurora, Colorado
HMD Research LLC
Orlando, Florida
Bolanos Clinical Research
Pembroke Pines, Florida
Augusta University-Rheumatology
Augusta, Georgia
Johns Hopkins University - Department of Medicine, Division of Rheumatology
Baltimore, Maryland
University of Minnesota-Dermatology
Minneapolis, Minnesota
University of Kansas Medical Center-Neuromuscular
Kansas City, Missouri
University of Pittsburgh
Pittsburgh, Pennsylvania
Austin Neuromuscular Center
Austin, Texas
Nerve and Muscle Center of Texas-Clinical research
Houston, Texas
Institute of Rheumatology - Rheumatology
Prague, Czechia
Hippokration Hospital - 2nd Department of Medicine and Laboratory
Athens, Greece
National and Kapodistrian University of Athens (Egnitio Hospital)
Athens, Greece
University General Hospital of Larissa
Larissa, Greece
Azienda Ospedaliero Universitaria Policlinico G. Rodolico-San Marco Di Catania (Vittorio Emanuele) - Reumatologia
Catania, Italy
Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San Marco Di Catania
Catania, Italy
Azienda Usl Toscana Centro
Florence, Italy
Arcispedale S. Maria Nuova
Reggio Emilia, Italy
Fondazione Policlinico Universitario A. Gemelli-IRCCS, UCSC - Scienze Mediche e Chirurgiche
Rome, Italy
Instytut Reumatologii im. Eleonory Reicher - Department of Connective Tissue Diseases
Warsaw, Poland
CHUAC - Complexo Hospitalario Universitario A Coruña - Rheumatology
A Coruña, Spain
Hospital Vall d'Hebron
Barcelona, Spain
Hospital Universitario Ramon y Cajal, Madrid - Rheumatology Department
Madrid, Spain
Doncaster Royal Infirmary (3466)
Doncaster, United Kingdom
Royal Free London NHS Foundation Trust
London, United Kingdom
University College London Hospitals NHS Foundation Trust- Neuromuscular Diseases
London, United Kingdom
Salford Royal Hospital, Barnes Clinical Research Facility
Salford, United Kingdom
Royal Wolverhampton Hospitals (6493)
Wolverhampton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.